UCB (OTCMKTS:UCBJY) Hits New 52-Week Low – What’s Next?

UCB SA (OTCMKTS:UCBJY) hit a new 52-week low during trading on Tuesday. The company traded as low as $111.47 and last traded at $111.5325, with a volume of 12,542 shares trading hands. The stock had previously closed at $113.96.

Analysts Set New Price Targets

Several research firms have commented on UCBJY. Jefferies Financial Group raised shares of UCB from a “moderate sell” rating to a “hold” rating in a research note on Monday, August 3rd. Barclays lowered UCB from a “strong-buy” rating to a “hold” rating in a report on Monday, June 15th. Finally, Zacks Research lowered UCB from a “strong-buy” rating to a “hold” rating in a report on Wednesday, September 16th. One research analyst has rated the stock with a Strong Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, UCB presently has a consensus rating of “Moderate Buy”.

UCB Trading Down 3.0%

The stock has a 50-day simple moving average of $122.64 and a 200 day simple moving average of $136.53.

UCB Company Profile

UCB SA is a Belgium-based biopharmaceutical company that discovers, develops and commercializes medicines for severe diseases, with a primary focus on neurology and immunology. The company serves patients and healthcare professionals in markets around the world through its research, manufacturing and commercial operations.

UCB’s medicines include Bimzelx (bimekizumab), used to treat several inflammatory conditions; Cimzia (certolizumab pegol), an immunology therapy; and Fintepla (fenfluramine), a treatment for certain severe epileptic syndromes.